Several cohort studies and trials have shown that individuals on GLP-1s have significantly lower markers of systemic inflammation, independent of weight loss
Although visible changes are what progress is often measured by, ultimately it isnt the most important thing
Jolanda van Hal November in review: GLP-1 breakthroughs, UPFs under fire, Novonesis advances healthy longevity Jolanda van Hal Key takeaways GLP-1 science, product pipelines, and consumer acceptance reached a pivotal point in November, reshaping nutrition, pharma, and metabolic health
Before adding high-dose L-Lysine to your daily regimen, especially if you are pregnant, nursing, or managing severe renal or cardiovascular conditions, please consult with a healthcare provider who is literate in complex chronic illnesses
Cardiovascular Diabetology , 19 (1), 156
At 0.25 mg, the dose is intentionally sub-therapeutic for weight loss